Center of Ophthalmology, University of Tuebingen, Tuebingen, Germany.
Clinique de l Oeil, Geneva, Switzerland.
Ocul Immunol Inflamm. 2022 May 19;30(4):907-914. doi: 10.1080/09273948.2020.1850799. Epub 2021 Feb 17.
PURPOSE/OBJECTIVES: to evaluate new onset uveitis or reactivated uveitis by biologic agents and characterize their features.
This is a multicenter, retrospective case series. Patients under biologic therapy were included if they developed uveitis for the first time or experienced intraocular inflammation which was different in location or laterality to previous inflammation.
Sixteen patients were identified. The underlying disorders included ankylosing spondylitis, juvenile idiopathic arthritis, rheumatoid arthritis, and Behçet's Disease. The biologic agents associated with a first episode of uveitis (n = 11) or with a new recurrence of uveitis (n = 5) were etanercept, adalimumab, abatacept, infliximab, and golimumab. Sarcoidosis based on bihilar lymphadenopathy, other computer tomography-findings, or biopsy was diagnosed in five patients under therapy with etanercep, adalimumab, and abatacept. Additionally, seven patients developed clinical changes in their uveitis pattern, suggesting sarcoid uveitis.
Biologic treatment-induced uveitis often presents as granulomatous disease.
评估生物制剂引起的新发性或复发性葡萄膜炎，并对其特征进行分析。
这是一项多中心、回顾性病例系列研究。纳入标准为接受生物治疗的患者首次发生葡萄膜炎或出现与既往炎症部位或侧别不同的眼内炎症。
共纳入 16 例患者，基础疾病包括强直性脊柱炎、幼年特发性关节炎、类风湿关节炎和贝赫切特病。11 例患者因使用依那西普、阿达木单抗、阿巴西普、英夫利昔单抗和戈利木单抗而首次发生葡萄膜炎，5 例患者因使用上述药物而出现葡萄膜炎复发。5 例接受依那西普、阿达木单抗和阿巴西普治疗的患者，根据双侧肺门淋巴结肿大、其他计算机断层扫描结果或活检诊断为结节病。此外，7 例患者葡萄膜炎模式发生临床变化，提示为结节病性葡萄膜炎。
生物制剂治疗引起的葡萄膜炎常表现为肉芽肿性疾病。
